InMed Pharmaceuticals Acquires Canna-Core for $1.5M
Ticker: INM · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, cannabinoid, drug-development
TL;DR
InMed buys Canna-Core for $1.5M in cash & stock to boost its cannabinoid drug pipeline.
AI Summary
InMed Pharmaceuticals Inc. announced on April 16, 2024, that it has entered into a definitive agreement to acquire Canna-Core Inc. for an aggregate purchase price of $1.5 million, consisting of $0.5 million in cash and $1.0 million in InMed common stock. This acquisition is expected to close on or about April 30, 2024, and is intended to enhance InMed's cannabinoid-based drug development pipeline.
Why It Matters
This acquisition aims to bolster InMed's drug development capabilities in the cannabinoid space, potentially leading to new therapeutic options.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the possibility that the acquired assets may not perform as expected, impacting InMed's financial and strategic goals.
Key Numbers
- $1.5M — Acquisition Price (Total value of the deal to acquire Canna-Core Inc.)
- $0.5M — Cash Component (Cash paid as part of the acquisition)
- $1.0M — Stock Component (Value of InMed common stock issued for the acquisition)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Acquiring company
- Canna-Core Inc. (company) — Acquired company
- $1.5 million (dollar_amount) — Aggregate purchase price
- $0.5 million (dollar_amount) — Cash portion of purchase price
- $1.0 million (dollar_amount) — Stock portion of purchase price
- April 16, 2024 (date) — Date of definitive agreement
- April 30, 2024 (date) — Expected closing date
FAQ
What is the primary strategic rationale behind InMed Pharmaceuticals' acquisition of Canna-Core Inc.?
The acquisition is intended to enhance InMed's cannabinoid-based drug development pipeline.
What is the total purchase price for Canna-Core Inc.?
The aggregate purchase price is $1.5 million.
How will the acquisition of Canna-Core Inc. be financed?
The acquisition will be financed by $0.5 million in cash and $1.0 million in InMed common stock.
When is the anticipated closing date for the acquisition?
The acquisition is expected to close on or about April 30, 2024.
What is the filing date of this Current Report on Form 8-K?
The filing date is April 16, 2024.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-16 14:39:35
Filing Documents
- ea0204004-8k_inmed.htm (8-K) — 37KB
- ea020400401ex99-1_inmed.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-033340.txt ( ) — 266KB
- inm-20240416.xsd (EX-101.SCH) — 3KB
- inm-20240416_def.xml (EX-101.DEF) — 26KB
- inm-20240416_lab.xml (EX-101.LAB) — 33KB
- inm-20240416_pre.xml (EX-101.PRE) — 22KB
- ea0204004-8k_inmed_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated April 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: April 16, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2